Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Innate Immun ; 7(3): 275-89, 2015.
Article in English | MEDLINE | ID: mdl-25591727

ABSTRACT

Endoplasmic reticulum aminopeptidase 1 (ERAP1) gene polymorphisms have been linked to several autoimmune diseases; however, the molecular mechanisms underlying these associations are not well understood. Recently, we demonstrated that ERAP1 regulates key aspects of the innate immune response. Previous studies show ERAP1 to be endoplasmic reticulum-localized and secreted during inflammation. Herein, we investigate the possible roles that ERAP1 polymorphic variants may have in modulating the innate immune responses of human peripheral blood mononuclear cells (hPBMCs) using two experimental methods: extracellular exposure of hPBMCs to ERAP1 variants and adenovirus (Ad)-based ERAP1 expression. We found that exposure of hPBMCs to ERAP1 variant proteins as well as ERAP1 overexpression by Ad5 vectors increased inflammatory cytokine and chemokine production, and enhanced immune cell activation. Investigating the molecular mechanisms behind these responses revealed that ERAP1 is able to activate innate immunity via multiple pathways, including the NLRP3 (NOD-like receptor, pyrin domain-containing 3) inflammasome. Importantly, these responses varied if autoimmune disease-associated variants of ERAP1 were examined in the assay systems. Unexpectedly, blocking ERAP1 cellular internalization augmented IL-1ß production. To our knowledge, this is the first report identifying ERAP1 as being involved in modulating innate responses of human immune cells, a finding that may explain why ERAP1 has been genetically associated with several autoimmune diseases.


Subject(s)
Aminopeptidases/immunology , Autoimmune Diseases/immunology , Immunity, Innate , Leukocytes, Mononuclear/immunology , Adenoviridae , Aminopeptidases/genetics , Animals , Autoimmune Diseases/genetics , Autoimmune Diseases/pathology , Carrier Proteins/genetics , Carrier Proteins/immunology , Cell Line , Humans , Inflammation/genetics , Inflammation/immunology , Inflammation/pathology , Interleukin-1beta/genetics , Interleukin-1beta/immunology , Leukocytes, Mononuclear/pathology , Mice , Minor Histocompatibility Antigens , NLR Family, Pyrin Domain-Containing 3 Protein , Transduction, Genetic
2.
Int Immunol ; 26(5): 291-303, 2014 May.
Article in English | MEDLINE | ID: mdl-24374770

ABSTRACT

The signaling lymphocytic activation molecule (SLAM) receptor-associated adaptor Ewing's sarcoma-associated transcript-2 (EAT-2) is primarily expressed in innate immune cells including dendritic cells (DCs), macrophages and NK cells. A recent human HIV vaccine study confirmed that EAT-2 expression was associated with the enhanced immunogenicity induced by the MRKAd5/HIV vaccine. We previously harnessed the capability of EAT-2 to modulate signaling mediated by SLAM receptors and demonstrated that by incorporating EAT-2 expression into vaccines, one could enhance innate and adaptive immune responses in mice, even in the face of pre-existing immunity to the vaccine vectors. Herein, we investigated the innate immune responses of human cells exposed to EAT-2-over-expressing vaccines. Our results demonstrate that EAT-2 over-expression can significantly alter the kinetics of critical pro-inflammatory cytokine and chemokine responses elaborated by human PBMCs. In addition, enhanced DC maturation and increased monocyte phagocytosis were observed in EAT-2-transduced human cells. We also found that EAT-2 over-expression improved antigen presentation by human cells. Moreover, EAT-2 over-expression increased the anti-tumor activity of human NK cells against K562 tumor cell targets. Many of these responses were extinguished with use of an EAT-2 variant carrying a mutant SH2 domain (R31Q), suggesting a critical role for the interaction between EAT-2 and SLAM receptors in mediating these responses. In conclusion, these results provide evidence that EAT-2 interacts with key components of multiple arms of the human innate immune system, and that this role highlights the potential for targeting EAT-2 functions so as to improve a number of human immunotherapeutic approaches, including vaccine development.


Subject(s)
Immune System/immunology , Immunity, Innate/immunology , Immunomodulation/immunology , Transcription Factors/immunology , Antigen Presentation/genetics , Antigen Presentation/immunology , Cells, Cultured , Coculture Techniques , Cytokines/immunology , Cytokines/metabolism , Cytotoxicity, Immunologic/immunology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Flow Cytometry , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , HEK293 Cells , HeLa Cells , Humans , Immune System/cytology , Immune System/metabolism , Immunity, Innate/genetics , Immunomodulation/genetics , Inflammation Mediators/immunology , Inflammation Mediators/metabolism , K562 Cells , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Microscopy, Fluorescence , Monocytes/immunology , Monocytes/metabolism , Mutation , Natural Cytotoxicity Triggering Receptor 2/immunology , Natural Cytotoxicity Triggering Receptor 2/metabolism , Phagocytosis/immunology , Transcription Factors/genetics , Transcription Factors/metabolism , src Homology Domains/genetics , src Homology Domains/immunology
3.
Autoimmunity ; 46(8): 497-508, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24028501

ABSTRACT

Ankylosing spondylitis (AS) is a chronic systemic arthritic disease that leads to significant disability and loss of quality of life in the ∼0.5% of the worldwide human population it affects. There is currently no cure for AS and mechanisms underlying its pathogenesis remain unclear. AS is highly genetic, with over 70% of the genetic risk being associated with the presence of HLA-B27 and endoplasmic reticulum aminopeptidase-1 (ERAP1) alleles. Furthermore, gene-gene interactions between HLA-B27 and ERAP1 AS risk alleles have recently been confirmed. Here, we demonstrate that various ERAP1 alleles can differentially mediate surface expression of antigens presented by HLA-B27 on human cells. Specifically, for all peptides tested, we found that an ERAP1 variant containing high AS risk SNPs reduced the amount of the peptide presented by HLA-B27, relative to low AS risk ERAP1 variants. These results were further validated using peptide catalysis assays in vitro, suggesting that high AS risk alleles have an enhanced catalytic activity that more rapidly destroys many HLA-B27-destined peptides, a result that correlated with decreased HLA-B27 presentation of the same peptides. These findings suggest that one mechanism underlying AS pathogenesis may involve an altered ability for AS patients harboring both HLA-B27 and high AS risk ERAP1 alleles to correctly display a variety of peptides to the adaptive arm of the immune system, potentially exposing such individuals to higher AS risk due to abnormal display of pathogen or self-derived peptides by the adaptive immune system.


Subject(s)
Alleles , Aminopeptidases/genetics , Antigen Presentation/immunology , HLA-B27 Antigen/immunology , Spondylitis, Ankylosing/genetics , Spondylitis, Ankylosing/immunology , Amino Acid Substitution , Epitopes/chemistry , Epitopes/immunology , Gene Expression , Genetic Predisposition to Disease , HLA-B27 Antigen/genetics , Humans , Minor Histocompatibility Antigens , Peptides/chemistry , Peptides/immunology , Polymorphism, Single Nucleotide , Reproducibility of Results , Transfection
4.
PLoS One ; 8(7): e69539, 2013.
Article in English | MEDLINE | ID: mdl-23894499

ABSTRACT

Endoplasmic reticulum aminopeptidase-1 (ERAP1) is a multifunctional, ubiquitously expressed enzyme whose peptide-trimming role during antigen processing for presentation by MHC I molecules is well established, however, a role for ERAP1 in modulating global innate immune responses has not been described to date. Here we demonstrate that, relative to wild type mice, mice lacking ERAP1 exhibit exaggerated innate immune responses early during pathogen recognition, as characterized by increased activation of splenic and hepatic NK and NKT cells and enhanced production of pro-inflammatory cytokines such as IL12 and MCP1. Our data also revealed that ERAP1 is playing a critical role in NK cell development and function. We observed higher frequencies of terminally matured NK cells, as well as higher frequencies of licensed NK cells (expressing the Ly49C and Ly49I receptors) in ERAP1-KO mice, results that positively correlated with an enhanced NK activation and IFNγ production by ERAP1-KO mice challenged with pro-inflammatory stimuli. Furthermore, during pathogen recognition, ERAP1 regulates IL12 production by CD11c(+) DCs specifically, with increases in IL12 production positively correlated with an increased phagocytic activity of splenic DCs and macrophages. Collectively, our results demonstrate a previously unrecognized, more central role for the ERAP1 protein in modulating several aspects of both the development of the innate immune system, and its responses during the initial stages of pathogen recognition. Such a role may explain why ERAP1 has been implicated by GWAS in the pathogenesis of autoimmune diseases that may be precipitated by aberrant responses to pathogen encounters.


Subject(s)
Aminopeptidases/metabolism , Immunity, Innate/physiology , Aminopeptidases/genetics , Animals , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Immunity, Innate/genetics , Interleukin-12/metabolism , Killer Cells, Natural/metabolism , Liver/cytology , Mice , Mice, Inbred C57BL , Mice, Knockout , Minor Histocompatibility Antigens , Reverse Transcriptase Polymerase Chain Reaction , Spleen/cytology
5.
Hum Immunol ; 74(8): 916-26, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23639554

ABSTRACT

The safe and effective activation of the innate and adaptive immune systems are crucial in the implementation of immunotherapeutic modalities for the prevention and treatment of human diseases. Eimeria antigen (EA) and its recombinantly expressed analog (rEA) are extremely effective activators of innate immunity in mice. The effects of rEA in the mouse are primarily mediated through the TLR11/12 MyD88 signaling system. Human cells lack functional TLR11 and TLR12, suggesting that rEA would not be effective in providing beneficial immune activation in humans. In the current report we provide definitive evidence that the treatment of human peripheral blood mononuclear cell (PBMC) cultures with rEA significantly up regulates CD69, CD107, NKG2D levels on NK cells. Furthermore, rEA stimulates human NK cell effector functions including increasing intracellular levels of IFNγ and Granzyme B. These responses are positively correlated with an improved capacity of rEA stimulated human PBMCs to kill NK cell-sensitive human K562 tumor cells. Importantly, rEA-triggered innate immune responses was not associated with increased pro-inflammatory cytokines and chemokines production. These data confirm a previously unidentified role for rEA in human immune cell activation, and suggests the utilization of rEA in immunotherapies against a variety of infectious diseases and cancers.


Subject(s)
Antigens, Protozoan/immunology , Eimeria/immunology , Immunity, Innate/immunology , Killer Cells, Natural/immunology , Lymphocyte Activation/immunology , Recombinant Proteins/immunology , Antigens, CD/metabolism , Antigens, Protozoan/pharmacology , Cells, Cultured , Cytokines/genetics , Cytokines/metabolism , Dendritic Cells/drug effects , Dendritic Cells/immunology , Dendritic Cells/metabolism , Gene Expression Regulation , Humans , Immunity, Innate/drug effects , Immunophenotyping , Killer Cells, Natural/drug effects , Killer Cells, Natural/metabolism , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Lymphocyte Activation/drug effects , NK Cell Lectin-Like Receptor Subfamily C/metabolism , Phenotype , Prohibitins , Recombinant Proteins/pharmacology , Toll-Like Receptor 4/agonists , Toll-Like Receptor 7/agonists , Toll-Like Receptor 8/agonists
6.
PLoS One ; 6(7): e22064, 2011.
Article in English | MEDLINE | ID: mdl-21760953

ABSTRACT

Despite recent advances in developing and licensing adjuvants, there is a great need for more potent formulations to enhance immunogenicity of vaccines. An Eimeria tenella derived antigen (rEA) augments immune responses against several pathogens in animal models and recently was confirmed to be safe for human use. In this study, we have analyzed the molecular mechanisms underlying rEA activity in mice, and confirmed that rEA activates multiple immune cell types, including DCs, macrophages, NK, B, and T cells. The rEA adjuvant also elicits the induction of pleiotropic pro-inflammatory cytokines, responses that completely depend upon the presence of the TLR adaptor protein MyD88. Surprisingly, we also found that the TRIF adaptor protein acts as a potent negative regulator of TLR agonist-triggered immune responses. For example, IL12 production and the induction of co-stimulatory molecule expression by DCs and IFNγ production by NK cells in vivo were significantly increased in rEA-treated TRIF-KO mice. Importantly, however, TRIF suppressive effects were not restricted to rEA-mediated responses, but were apparent in LPS- or ODN2006-activated DCs as well. Taken together, our findings confirm that rEA is a potent adjuvant, triggering robust activation of the innate immune system, in a manner that is augmented by MyD88 and inhibited by TRIF; thereby unveiling the potential complexities of modulating TLR activity to augment vaccine efficacy.


Subject(s)
Adaptor Proteins, Vesicular Transport/metabolism , Dendritic Cells/immunology , Toll-Like Receptors/agonists , Animals , Antigens, Protozoan/immunology , B-Lymphocytes/immunology , Chemokines/metabolism , Dendritic Cells/cytology , Dendritic Cells/parasitology , Eimeria tenella/immunology , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Inflammation Mediators , Killer Cells, Natural/immunology , Lymphocyte Activation/immunology , Macrophages/cytology , Macrophages/immunology , Mice , Mice, Inbred C57BL , Models, Immunological , Myeloid Differentiation Factor 88/metabolism , Natural Killer T-Cells/immunology , Phosphorylation , Prohibitins , Toll-Like Receptors/immunology
7.
Int Immunopharmacol ; 8(8): 1089-94, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18550012

ABSTRACT

Recombinant Eimeria antigen (rEA) has been shown to have potent anticancer and antiviral activity in respective mouse disease models, presumably through robust immune stimulation that occurs via TLR11, a pattern recognition receptor that recognizes profilin-like proteins expressed on apicomplexan protozoans. Comparable immunostimulatory activity in other species has yet to be demonstrated. Since rEA is known to be highly effective in treating Punta Toro virus (PTV) infection in mice, its ability to elicit protective immunity in the hamster PTV infection model was investigated. rEA was given alone, or in combination with IL-18 or IL-2, and virally challenged hamsters were observed for mortality. Cytokine transcript profiles for IL-12p40, IL-21, IFN-gamma and TNF-alpha were assessed to evaluate the induction of these inflammatory mediators known to be induced in mice following exposure to rEA. A dose of 100 microg of rEA, given once 4 h prior to viral challenge, and a second time on day 3 of the infection, was found to be the most effective prophylactic therapy protecting 60% of treated hamsters from mortality, compared to only 5-10% observed in animals receiving placebo. Increased expression of IFN-gamma and IL-12p40 was evident following treatment with rEA. The data suggest that rEA does induce host antiviral responses in hamsters that result in significant protection from death, although determining the most appropriate dose for intervention in other species, including humans, will likely be challenging.


Subject(s)
Antigens, Protozoan/immunology , Bunyaviridae Infections/immunology , Bunyaviridae Infections/prevention & control , Eimeria/immunology , Phlebovirus/immunology , Animals , Antigens, Protozoan/administration & dosage , Bunyaviridae Infections/mortality , Cricetinae , Female , Interferon-gamma/genetics , Interferon-gamma/immunology , Interferon-gamma/metabolism , Interleukin-12 Subunit p40/genetics , Interleukin-18/administration & dosage , Interleukin-18/immunology , Interleukin-2/administration & dosage , Interleukin-2/immunology , Mesocricetus , Prohibitins , Recombinant Proteins/immunology , Transcription, Genetic
8.
Clin Cancer Res ; 14(10): 3089-97, 2008 May 15.
Article in English | MEDLINE | ID: mdl-18483376

ABSTRACT

PURPOSE: A recombinant protein product, rBBX-01, is the first innate immunostimulator derived from a protozoan (Eimeria protozoan) and has shown potent preclinical in vivo and in vitro activities. This phase I trial was done to determine the safety and basic pharmacology of rBBX-01. EXPERIMENTAL DESIGN: Eligible patients had recurrent incurable gynecologic malignancies. The study was divided into three components: a starting low-dose phase (0.85, 2.0, and 4.0 microg/m2), an intrapatient dose acceleration phase (4.0-1,024.0 microg/m2), and a high-dose phase (1,000 and 2,000 microg/m2). All treatment doses were administered daily for 5 days. Patients were allowed a second cycle of treatment if there was evidence of response. RESULTS: Sixteen patients received a total of 20 cycles of rBBX-01. All patients tolerated the drug well, exhibiting no local or systemic, acute or delayed, adverse reactions. Plasma levels of rBBX-01 were detectable in all patients over the entire dose range, although changes in the pharmacodynamic marker (interleukin-12) exhibited patient-to-patient variability. Of 14 patients with ovarian, primary peritoneal, or endometrial cancer with elevated CA125 biomarkers at the start of treatment, 4 responded with decreased levels of CA125. One patient showed decreasing CA125 levels for 10 months and received no additional chemotherapy for 11 months. Those patients exhibiting reductions in CA125 also exhibited increased levels of plasma interleukin-12 during the week of therapy. CONCLUSION: The immunostimulator rBBX-01 was safe in multidose regimens in heavily pretreated women. Of the 14 patients with elevated CA125 levels, an approximately 30% response rate was detected. rBBX-01 should receive additional testing in the clinical setting.


Subject(s)
Genital Neoplasms, Female/drug therapy , Immunologic Factors/administration & dosage , Immunologic Factors/pharmacokinetics , Protozoan Proteins/administration & dosage , Protozoan Proteins/pharmacokinetics , Adult , Aged , Animals , CA-125 Antigen/blood , CA-125 Antigen/drug effects , Cricetinae , Dose-Response Relationship, Drug , Eimeria , Female , Humans , Immunologic Factors/adverse effects , Mice , Middle Aged , Protozoan Proteins/adverse effects , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Recombinant Proteins/pharmacokinetics
9.
Med Hypotheses ; 71(1): 104-10, 2008.
Article in English | MEDLINE | ID: mdl-18343044

ABSTRACT

Colon cancer in humans results in considerable morbidity and mortality throughout most of the world. During the twentieth century, there was a rapid rise in colon cancer within modernizing countries that has not been adequately explained, although the role of diet has been widely explored. Previously, we showed that the presence of the endemic Eimeria spp. protozoan in intestinal tissues is associated with regions of low tumorigenesis in the large and small bovine intestine and that an Eimeria surface protein is a potent activator of dendritic cells and a useful immunomodulator, with anti-cancer and anti-viral properties. Therefore, we hypothesize that the persistent presence of such an intestinal protozoan enhances immunosurveillance by elevating the intestinal alert status and that the loss of these organisms could lead to a higher incidence of colon cancer. Preliminary support of this hypothesis derives from the observations that domestic animals, known to maintain this protozoan, have very low colon cancer incidence. We propose that this also may occur in human populations that use human excrement (night soil) as a fertilizer, a practice that serves to complete the life cycle of this type of microbe. We examine some evidence for this hypothesis in Japan's mortality patterns, where we show that colon cancer increased after the cessation of night soil use, but before the change to a western diet. We conclude that this hypothesis, a variation of the hygiene hypothesis, is worth further consideration and continued elaboration.


Subject(s)
Colonic Neoplasms/immunology , Eimeria/immunology , Immunologic Surveillance , Intestines/immunology , Intestines/parasitology , Animals , Coccidiosis/immunology , Coccidiosis/parasitology , Colonic Neoplasms/epidemiology , Colonic Neoplasms/parasitology , Colonic Neoplasms/prevention & control , Female , Humans , Japan/epidemiology , Male , Mice , Models, Immunological
10.
Int J Cancer ; 114(5): 756-65, 2005 May 01.
Article in English | MEDLINE | ID: mdl-15609305

ABSTRACT

The small intestine (SI) of vertebrates exhibits low tumorigenesis and rarely supports metastatic growth from distant tumors. Many theories have been proposed to address this phenomenon, but none has been consistently supported. One candidate mechanism is that the vast immunologic compartment of the SI provides a heightened level of tumor immunosurveillance. Consistent with this, we have identified a molecule of low abundance from bovine SI that has the hallmarks of a potent immunostimulant and may be associated with the natural suppression of cancer in the intestinal tract. The protein originates from an endemic gut protozoan, Eimeria spp., and is homologous to the antigen 3-1E previously isolated from the avian apicomplexan E. acervulina. We show here that it is a very potent stimulator of IL-12 release from dendritic cells, upregulates inflammatory modulators in vivo (IL-12, MCP-1, IL-6, TNF-alpha and INF-gamma) and has antitumor properties in mice. In addition, it is synergistic in vitro with anti-CD40 antibody, IFN-gamma, IL-4 and GM-CSF; is active across species barriers in vivo; and has no observable toxicity. Based on these activities, we speculate that it is an inducer of protozoan-targeted innate immunity, which may explain its potential benefit to the intestinal tract and potency as an agent in cancer immunotherapy.


Subject(s)
Anticarcinogenic Agents/pharmacology , Dendritic Cells/metabolism , Eimeria/metabolism , Interleukin-12/metabolism , Intestinal Neoplasms/prevention & control , Amino Acid Sequence , Animals , CD40 Antigens/metabolism , Cattle , Cell Membrane/metabolism , Chemokine CCL2/metabolism , Culture Media, Conditioned/metabolism , Cytokines/metabolism , Dendritic Cells/cytology , Dose-Response Relationship, Drug , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Immunotherapy/methods , Interferon-gamma/metabolism , Interleukin-4/metabolism , Interleukin-6/metabolism , Intestinal Neoplasms/metabolism , Intestines/parasitology , Killer Cells, Natural/metabolism , Male , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Recombinant Proteins/chemistry , Sequence Homology, Amino Acid , Time Factors , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...